As mesenchymal tumor cells express high levels of active TBK1 (105) and are associated with aggressive disease, metastasis, and poor patient outcomes (30), targeting TBK1 in RAS-driven cancers is a promising alternative strategy to reduce the tumor-promoting effects of KRAS-driven EMT. Here, TBK1 is linked to neoplasm.